NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates

NeOnc shifts focus from a now-removed preferred stock overhang to funding and advancing its CNS oncology pipeline.

Rhea-AI Summary

NeOnc Technologies (NTHI) redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for $6 million in cash, issuing no new common shares and removing a potential source of discounted-share conversion.

The redemption follows a recently announced $15 million registered direct offering, which the company said was structured to fund this buyback and simplify the capital structure. The Series A, issued in June for $5 million, carried a four-month cash-redemption window and could have converted into common stock at 80% of the lowest closing price over the prior five trading days, subject to a $1 floor, had it not been redeemed.

Alongside this capital move, NeOnc highlighted clinical progress: NEO100 reported topline Phase 2a data in recurrent IDH1-mutant high-grade glioma with six-month progression-free survival of 48.9% versus a 20% benchmark and median overall survival of 26.09 months, while NEO212 completed Phase 1 dose escalation, set a recommended Phase 2 dose of 610 mg, and received UAE IND authorization.

Positive

• Series A preferred fully redeemed for $6 million cash with no common issued, removing a discounted-conversion overhang
• $15 million registered direct offering completed and structured to support the preferred redemption
• NEO100 Phase 2a six-month PFS 48.9% vs 20% prespecified benchmark in recurrent IDH1-mutant high-grade glioma
• NEO100 median overall survival reported at 26.09 months in Phase 2a topline data
• NEO212 completed Phase 1 dose escalation and set a 610 mg recommended Phase 2 dose
• NEO212 received UAE IND authorization, expanding its international development pathway

Negative

• $6 million cash outlay required to redeem Series A preferred shares
• Series A preferred was issued for $5 million in June and redeemed shortly after for $6 million

News Explained

The redemption is complete with no common shares issued; the $15 million offering equals 286.5 days of the last reported operating cash use, while cash reported at June 30, 2026 equals 37.7 days at that rate.

Sources and calculations

• NeOnc Sept. 17, 2026 press release (2026-09-17)
• NeOnc latest quarterly fundamentals (2026-06-30)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $15,000,000 / ($4,765,181 / 91) = 286.5 days
• Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,973,420 / ($4,765,181 / 91) = 37.7 days

Key Figures

Preferred shares redeemed: 6,000 shares Cash redemption: $6 million Registered direct offering: $15 million +3 more

Preferred shares redeemed

6,000 shares

Series A convertible preferred stock

Cash redemption

$6 million

Cash paid to redeem all outstanding Series A preferred shares

Registered direct offering

$15 million

Announced days before the preferred-stock redemption

Conversion price

80% of the lowest closing price

Series A conversion terms, subject to a $1 floor

Six-month progression-free survival

48.9%

NEO100 Phase 2a results versus a 20% benchmark

Median overall survival

26.09 months

NEO100 Phase 2a results

Historical Context

1 past event · Latest: Sep 09

1 event

1. Sep 09

   Registered offering

   24h Move

   -11.1%

   Registered offering proceeds were allocated to redeem Series A convertible preferred stock.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

convertible preferred stock, registered direct offering, progression-free survival

3 terms

convertible preferred stock financial

"all 6,000 outstanding shares of Series A Convertible Preferred Stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

registered direct offering financial

"announced a $15 million registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

progression-free survival medical

"six-month progression-free survival of 48.9%"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies (NASDAQ: NTHI) just removed a potentially significant overhang from its capital structure, redeeming all 6,000 outstanding shares of Series A Convertible Preferred Stock for $6 million in cash, with zero common shares issued in the process.

The move comes only days after NeOnc announced a $15 million registered direct offering, creating a notable one-two punch: fresh capital for the clinical-stage biotech while simultaneously eliminating a preferred security that could have converted into common stock at a substantial discount. The company said the financing was specifically structured to support the redemption.

“We made a deliberate decision to redeem the Series A Preferred Stock in cash and eliminate the potential dilution these securities represented for our shareholders,” CEO and Executive Chairman Amir F. Heshmatpour said.

The timing is particularly notable because the preferred stock's conversion terms could have become more consequential. Issued in June for $5 million in gross proceeds, the Series A shares carried a four-month cash-redemption window. Had NeOnc not redeemed them, the stated value would have increased and holders could have elected to convert into common stock at 80% of the lowest closing price during the preceding five trading days, subject to a $1 floor.

Instead, NeOnc has effectively shut that door.

The company isn't making the capital-structure cleanup in isolation. NeOnc is entering the next phase of its CNS cancer story with two clinical programs moving forward. NEO100 recently delivered topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, with the company reporting six-month progression-free survival of 48.9% versus a prespecified 20% benchmark and median overall survival of 26.09 months.

Meanwhile, NEO212 has completed Phase 1 dose escalation, established a recommended Phase 2 dose of 610 mg, and received UAE IND authorization as NeOnc expands its international development pathway.

That puts the latest preferred-stock redemption into a larger narrative: NeOnc is attempting to simplify its capitalization while pushing its drug pipeline toward increasingly important clinical and regulatory milestones.

“We are focused on translating clinical progress into lasting value for patients and shareholders,” Heshmatpour said.

NEO100 and NEO212 remain investigational programs, but the capital-structure move is clear: NeOnc chose to eliminate a potential source of discounted-share conversion before it became available.

For investors watching NeOnc, the story is therefore shifting from simply raising money to how efficiently that capital can be deployed against an advancing CNS oncology pipeline, with one potentially dilutive security now off the table.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the conversion terms of NeOnc's Series A Convertible Preferred Stock that have now been eliminated?

The Series A shares could have converted into common stock at 80% of the lowest closing price during the preceding five trading days, subject to a $1 per share floor. The shares also had a four-month cash-redemption window and a stated value that would have increased over time if not redeemed.

How does the recent $15 million financing relate to the preferred stock redemption?

The company stated that the $15 million registered direct offering was specifically structured to support the $6 million cash redemption of all 6,000 outstanding Series A Convertible Preferred shares, aligning new capital with the goal of simplifying the capital structure.

What key efficacy outcomes were reported for NEO100 in the Phase 2a trial?

In recurrent IDH1-mutant high-grade glioma, NEO100 topline Phase 2a results included a six-month progression-free survival rate of 48.9% versus a prespecified 20% benchmark and a median overall survival of 26.09 months, with the program remaining investigational.

What is the current development status of NEO212?

NEO212 has completed Phase 1 dose escalation, established a recommended Phase 2 dose of 610 mg, and obtained UAE IND authorization, supporting an expanded international development pathway while the therapy remains investigational.